All Outputs (3)

Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index (2018)
Journal Article
Sze, S., Pellicori, P., Kazmi, S., Rigby, A., Cleland, J. G., Wong, K., & Clark, A. L. (2018). Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index. JACC: Heart Failure, 6(6), 476-486. https://doi.org/10.1016/j.jchf.2018.02.018

Objectives The authors sought to report the prevalence, clinical associations, and prognostic consequences of malnutrition in outpatients with heart failure (HF). Background Malnutrition may be common in HF and associated with adverse outcomes, but... Read More about Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure: A Comparison With Body Mass Index.

Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease (2013)
Journal Article
Kahal, H., Abouda, G., Rigby, A. S., Coady, A. M., Kilpatrick, E. S., & Atkin, S. L. (2014). Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clinical Endocrinology, 81(4), 523-528. https://doi.org/10.1111/cen.12369

© 2013 John Wiley & Sons Ltd. Introduction: Nonalcoholic fatty liver disease (NAFLD) has been linked to polycystic ovary syndrome (PCOS) and carries an increased risk of liver cirrhosis. Procollagen type 3 amino-terminal peptide (PIIINP) is an inde... Read More about Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design (2013)
Journal Article
Kotecha, D., Manzano, L., Altman, D. G., Krum, H., Erdem, G., Williams, N., …Beta-Blockers in Heart Failure Collaborative Group. (2013). Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design. Systematic reviews, 2(1), Article 7. https://doi.org/10.1186/2046-4053-2-7

The Beta-Blockers in Heart Failure Collaborative Group (BB-HF) was formed to obtain and analyze individual patient data from the major randomized controlled trials of beta-blockers in heart failure. Even though beta-blockers are an established treatm... Read More about Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.